Revolutionising the Worldwide Molecular Diagnostics Market

Randox Molecular Diagnostics offers a range of molecular Arrays and assay formats, providing diagnostic, prognostic  and response to therapy solutions for a range of conditions including colorectal cancer, sexually transmitted infections and respiratory pathogens, with many more in development. The versatility of the Randox multiplex PCR and proprietary Biochip Array Technology is exemplified by the broad range of array formats available. These include: SNP Genotyping - based on an innovative primer design, which can discriminate sequences which differ only at one base;

Gene Expression - harnessing gene expression, particularly in a multiplex array, can provide a powerful insight into disease processes, such as cancer progression; Pathogen Detection - for rapid, sensitive, multiplex detection of viral, bacterial and protozoan pathogens; and Mutation Detection - a rapid mutation profiling array, consisting of a highly multiplexed PCR coupled to hybridisation of target DNA sequences to spatially tethered probes on a biochip array.

Our Sexually Transmitted Infection (STI) Array is capable of simultaneously detecting ten of the most common STIs from a single patient sample. STIs represent a serious public health issue and as many are asymptomatic, the risk of unhindered spread is increased. Simultaneous screening for multiple STIs will identify specific viral, protozoan or bacterial pathogens therefore permitting targeted therapy whilst also detecting secondary infections. The Respiratory Pathogens Array simultaneously detects up to 22 viral and bacterial infectious agents of the respiratory tract from Bronchoalveolar lavage, Nasopharyngeal swab, Sputum or Saliva. By detecting both viral and bacterial pathogens simultaneously, this array provides a rapid and more cost effective diagnostic tool than existing methods, the majority of which only look for single pathogens. Personalised cancer medicine based on genetic profiling of individual tumours is regarded as the treatment strategy of the future. In respect of this, Randox Molecular Diagnostics will

soon be launching a KRAS/BRAF/PIK3CA Array for the rapid and accurate detection of mutations to stratify patients for anti-EGFR-targeted therapy. This is important, as recent clinical evidence indicates that in addition to KRAS mutational status, other molecular alterations such as BRAF and PIK3CA mutations can occur in a tumour, precluding response to anti-EGFR therapy.